XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Inventories
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Inventories of $8.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $9.50M, a 25.47% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was -$851.00K, a 123.53% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $4.01M, a 27.86% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $4.08M, a 289.79% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for fiscal 2025 was $19.29M, a 119.61% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for fiscal 2024 was $8.78M, a 40.68% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for fiscal 2023 was $14.80M, a 98.31% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in inventories for fiscal 2022 was $7.46M, a 0.63% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.65M 10-Q · filed 2026-08-06 | $12.66M derived: sum of 3 quarters · filed 2026-08-06 | $16.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$851.00K 10-Q · filed 2026-05-07 | $3.16M derived: sum of 2 quarters · filed 2026-05-07 | $7.25M derived: sum of 3 quarters · filed 2026-05-07 | $14.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.10M derived: sum of 2 quarters · filed 2026-03-02 | $15.67M derived: sum of 3 quarters · filed 2026-08-06 | $19.29M 10-K · filed 2026-03-02 |
| 2025-09-30 | $4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.66M derived: sum of 2 quarters · filed 2026-08-06 | $15.28M 10-Q · filed 2025-11-06 | $18.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.19M 10-Q · filed 2026-08-06 | $14.33M derived: sum of 3 quarters · filed 2026-08-06 | $15.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.62M 10-Q · filed 2026-05-07 | $6.75M derived: sum of 2 quarters · filed 2026-05-07 | $7.80M derived: sum of 3 quarters · filed 2026-05-07 | $10.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.18M derived: sum of 2 quarters · filed 2026-03-02 | $6.45M derived: sum of 3 quarters · filed 2026-03-02 | $8.78M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.31M derived: sum of 2 quarters · filed 2025-11-06 | $5.64M 10-Q · filed 2025-11-06 | $7.05M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.60M 10-Q · filed 2025-08-07 | $6.00M derived: sum of 3 quarters · filed 2026-03-02 | $8.15M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $2.33M 10-Q · filed 2025-05-08 | $3.73M derived: sum of 2 quarters · filed 2026-03-02 | $5.89M derived: sum of 3 quarters · filed 2026-03-02 | $13.32M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.55M derived: sum of 2 quarters · filed 2026-03-02 | $10.99M derived: sum of 3 quarters · filed 2026-03-02 | $14.80M 10-K · filed 2026-03-02 |
| 2023-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $9.59M derived: sum of 2 quarters · filed 2024-11-08 | $13.40M 10-Q · filed 2024-11-08 | $18.91M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $7.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $11.25M 10-Q · filed 2024-08-08 | $16.75M derived: sum of 3 quarters · filed 2025-03-06 | $18.41M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $3.82M 10-Q · filed 2024-05-09 | $9.32M derived: sum of 2 quarters · filed 2025-03-06 | $10.98M derived: sum of 3 quarters · filed 2025-03-06 | $11.13M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $7.16M derived: sum of 2 quarters · filed 2025-03-06 | $7.31M derived: sum of 3 quarters · filed 2025-03-06 | $7.46M 10-K · filed 2025-03-06 |
| 2022-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.80M derived: sum of 2 quarters · filed 2023-11-09 | $1.96M 10-Q · filed 2023-11-09 | $4.23M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $305.00K 10-Q · filed 2023-08-08 | $2.58M derived: sum of 3 quarters · filed 2024-03-06 | $3.84M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $157.00K 10-Q · filed 2023-05-09 | $2.43M derived: sum of 2 quarters · filed 2024-03-06 | $3.69M derived: sum of 3 quarters · filed 2024-03-06 | $4.09M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $3.53M derived: sum of 2 quarters · filed 2024-03-06 | $3.94M derived: sum of 3 quarters · filed 2024-03-06 | $7.42M 10-K · filed 2024-03-06 |
| 2021-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.66M derived: sum of 2 quarters · filed 2022-11-09 | $5.14M 10-Q · filed 2022-11-09 | $6.83M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $404.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $3.89M 10-Q · filed 2022-08-10 | $5.57M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $3.48M 10-Q · filed 2022-05-11 | $5.17M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $5.14M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $3.46M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |